Joseph P Lyssikatos

USPTO Granted Patents = 139 (Patent Applications = 48)

CIPO Patents = 18 (Patent Applications = 8)

EPO Patents = 43 (Patent Applications = 52)

Average Co-Inventor Count = 4.9

ph-index = 15

Forward Citations = 855(Granted Patents)

Forward Citations (Not Self Cited) = 630(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Gales Ferry, CT (US) (1999 - 2003)
Piedmont, CO (US) (2013)
Superior, CO (US) (2003 - 2017)
Cambridge, MA (US) (2017 - 2022)
Boulder, CO (US) (2015 - 2023)
South San Francisco, CA (US) (2016 - 2023)
Piedmont, CA (US) (2010 - 2024)

Company Filing History:

Denali Therapeutics Inc.

Ventirx Pharmaceuticals, Inc.

Enliven Therapeutics, Inc.

patent

9. 1 out of 4,948

Hoffmann-la Roche Inc.

11. 1 out of 832,880

Other

patents

where one patent can have more than one assignee

Years Active: 1999-2025

Loading Chart...

Areas of Expertise:

Bcr-Abl Tyrosine Kinases

Bruton's Tyrosine Kinase

Receptor Tyrosine Kinase Inhibitors

Deuterated Compounds

Quinazoline Derivatives

Irak4 Inhibitors

Lrrk2 Inhibitors

Biaryl Inhibitors

Sulfonamide Compounds

Mitotic Kinesin Inhibitors

Heterocyclic Compounds

Hyperproliferative Diseases

139 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12358928 - Compounds, compositions and methods (2025-07-15),

2. 12240846 - 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases (2025-03-04),

3. 12214058 - Imaging methods using deuterated compounds (2025-02-04),

4. 12171739 - N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases (2024-12-24),

5. 11858926 - Inhibiting agents for bruton's tyrosine kinase (2024-01-02),

6. 11840529 - Substituted pyrimidines as LRKK2 inhibitors (2023-12-12),

7. 11834439 - Compounds, compositions, and methods (2023-12-05),

8. 11807649 - Fused tetracyclic quinazoline derivatives as inhibitors of ErbB2 (2023-11-07),

9. 11807638 - 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases (2023-11-07),

10. 11767321 - 5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases (2023-09-26),

11. 11591316 - Compounds, compositions, and methods (2023-02-28),

12. 11572356 - Biaryl inhibitors of Bruton's tyrosine kinase (2023-02-07),

13. 11504440 - Deuterated compounds (2022-11-22),

14. 11427577 - Inhibiting agents for Bruton's tyrosine kinase (2022-08-30),

15. 11427561 - IRAK4 inhibiting agents (2022-08-30),

Title: The Inventor Joseph P Lyssikatos: Pioneering Innovations in Piedmont, CA

Introduction: Joseph P Lyssikatos is a renowned inventor based in Piedmont, CA, known for his groundbreaking contributions to various fields through his innovative creations.

Latest Patents: Joseph P Lyssikatos holds several patents in diverse areas, showcasing his versatility and creativity in inventing new solutions to complex problems.

Career Highlights: Throughout his illustrious career, Joseph P Lyssikatos has consistently pushed the boundaries of innovation, earning recognition for his cutting-edge inventions that have had a significant impact on industries worldwide.

Collaborations: Joseph P Lyssikatos has collaborated with leading experts and organizations in his field, fostering a culture of innovation and knowledge-sharing to drive progress and development in the technological landscape.

Conclusion: Joseph P Lyssikatos stands as a visionary inventor whose passion for innovation and relentless pursuit of excellence continue to inspire generations of inventors and shape the future of technology.

This text is generated by artificial intelligence and may not be accurate.